Compare Abbott Laboratories (ABT) vs Linde PLC (LIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Linde PLC — how do they compare? Abbott Laboratories trades at $109.94 (market cap $187.95B), while Linde PLC trades at $493.11 (market cap $227.01B). The key difference: Linde PLC is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| ABT | LIN | |
|---|---|---|
Market Cap | $187.95B | $227.01B |
Sector | Health | Basic Materials |
52-Week High | $136.62 | $546.64 |
52-Week Low | $82.57 | $389.38 |
Enterprise Value | $214.96B | $250.13B |
Dividend Yield | 2.32% | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $107.80, down slightly by 0.14% today. The stock shows a bullish technical signal with strong moving average support and a consensus analyst price target of $120.70. Recent earnings beat expectations in Q1 and Q2 2026, while revenue grew to $44.33 billion in 2025. The company secured a CE Mark for its Libre Duo glucose-ketone sensor, highlighting innovation in diabetes care.
The outlook remains positive given analyst consensus and recent product approvals, but risks include competitive pressures and macroeconomic volatility. Upside potential exists if earnings momentum continues, though valuation multiples are above industry averages, warranting caution on significant expansion.
Linde (LIN) trades at $489.98, showing minimal daily change. The stock exhibits strong fundamentals with consistent earnings beats, a 20.43% net income margin, and robust cash flow. However, technical indicators signal a bearish short-term trend, with the price near the pivot point of $490. Recent news highlights sustainability leadership and Q1 2026 EPS growth of 10% year-over-year, though a DCF analysis from GuruFocus on June 1, 2026, suggested potential overvaluation at a $327 fair value.
The investment outlook is supported by solid profitability and a bullish analyst consensus with a $553.60 price target, but risks include elevated valuation multiples and increasing debt-to-asset ratios. The stock's near-term direction may hinge on Q3 2026 earnings versus the $4.53 estimate, with technical resistance at $493 posing a challenge to upside momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
